TSE:ATE Antibe Therapeutics (ATE) Stock Price, News & Analysis → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free ATE Stock Alerts C$0.30 +0.04 (+13.46%) (As of 04/8/2024) Add Compare Share Share Today's RangeC$0.26▼C$0.3550-Day RangeC$0.17▼C$0.4552-Week RangeC$0.15▼C$1.23Volume167,042 shsAverage Volume135,475 shsMarket CapitalizationC$15.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider Trades Get Antibe Therapeutics alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Antibe Therapeutics Stock (TSE:ATE)Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More ATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATE Stock News HeadlinesApril 9, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - ATEMarch 4, 2024 | finance.yahoo.comAntibe Announces Unfavorable Decision in Arbitration With Nuance PharmaFebruary 1, 2024 | finance.yahoo.comAntibe Extends Early Warrant Exercise Incentive ProgramDecember 31, 2023 | morningstar.comAntibe Therapeutics Inc ATEDecember 29, 2023 | finance.yahoo.comAntibe Announces Early Warrant Exercise Incentive ProgramNovember 13, 2023 | finance.yahoo.comAntibe Reports Q2 2024 Interim Financial and Operating ResultsNovember 8, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)November 6, 2023 | baystreet.caHercules at 52-Week High on Barrick HookupNovember 1, 2023 | baystreet.caAntibe at 52-Week High on NewsNovember 1, 2023 | finance.yahoo.comAntibe Completes First Clinical Study of Otenaproxesul’s New FormulationOctober 18, 2023 | benzinga.comAntibe Initiates First Clinical Study of Otenaproxesul's New FormulationSeptember 28, 2023 | ca.finance.yahoo.comStocks in play: Antibe Therapeutics Inc.September 28, 2023 | finance.yahoo.comAntibe Receives Approval to Initiate PK/PD Study of OtenaproxesulSeptember 6, 2023 | investing.comAntibe Therapeutics Inc. (ATE)August 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 17, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)June 30, 2023 | finance.yahoo.comAntibe Therapeutics Inc.'s (TSE:ATE) Path To ProfitabilityJune 23, 2023 | baystreet.caLast Week of June Looks EventfulJune 16, 2023 | travel.usnews.comBest Times To Visit AntibesJune 13, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Monday (ATE)June 3, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Friday (ATE)May 19, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Thursday (ATE)April 28, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Thursday (ATE)April 25, 2023 | finance.yahoo.comAntibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials SummitSee More Headlines Receive ATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/18/2024Next Earnings (Estimated)7/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ATE CUSIPN/A CIKN/A Webwww.antibethera.com Phone+1-905-5705103FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.35) Trailing P/E RatioN/A Forward P/E Ratio0.56 P/E GrowthN/ANet IncomeC$-18,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.72% Return on Assets-19.13% Debt Debt-to-Equity Ratio0.29 Current Ratio10.06 Quick Ratio9.58 Sales & Book Value Annual SalesC$9.71 million Price / Sales1.61 Cash FlowC$0.48 per share Price / Cash Flow0.61 Book ValueC$0.49 per share Price / Book0.60Miscellaneous Outstanding Shares53,010,000Free FloatN/AMarket CapC$15.64 million OptionableNot Optionable Beta0.19 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Daniel Marcel Legault J.D. (Age 66)L.L.B., President, CEO, Secretary & Director Comp: $744.67kMr. Alain Wilson M.B.A.MBA, Chief Financial OfficerMr. Scott Curtis C.F.A.M.Eng, Chief Operating OfficerDr. David James Vaughan Ph.D. (Age 74)Chief Development Officer Comp: $406.58kDr. Joseph Stauffer D.O. (Age 58)M.B.A., Chief Medical Officer Comp: $1.11MDr. Ana StegicExecutive Director of Clinical OperationsMs. Christina Cameron B.B.A.Vice President of Investor RelationsMr. Philip SternVice President of CommunicationsMore ExecutivesKey CompetitorsHelix BioPharmaTSE:HBPEmerald Health TherapeuticsCVE:EMHProMIS NeurosciencesTSE:PMNSmall PharmaCVE:DMTCovalon TechnologiesCVE:COVView All CompetitorsInsidersDaniel Marcel LegaultBought 20,000 shares on 3/7/2024Total: C$10,000.00 ($0.50/share)Joseph StaufferBought 24,000 shares on 3/6/2024Total: C$9,600.00 ($0.40/share)View All Insider Transactions ATE Stock Analysis - Frequently Asked Questions Should I buy or sell Antibe Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATE, but not buy additional shares or sell existing shares. View ATE analyst ratings or view top-rated stocks. How have ATE shares performed in 2024? Antibe Therapeutics' stock was trading at C$0.93 at the beginning of 2024. Since then, ATE stock has decreased by 68.3% and is now trading at C$0.30. View the best growth stocks for 2024 here. When is Antibe Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ATE earnings forecast. Is Antibe Therapeutics a good dividend stock? Antibe Therapeutics (TSE:ATE) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%. How do I buy shares of Antibe Therapeutics? Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:ATE) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.